We advised HighTide Therapeutics on its IPO and HKEX listing

Davis Polk advised HighTide Therapeutics, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A / Regulation S. The net proceeds from the offering amounted to approximately HK$194.1 million.

Established in 2011, HighTide is a leading biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. HighTide has developed a product pipeline of one core product and other four product candidates in-house. Its core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Yang Chu, counsel Jennifer Ng, counsel - registered foreign lawyer Jennifer (Yujia) Jiang and registered foreign lawyer Cecilia Chen. Counsel Alon Gurfinkel and associate Ya Sheng Lin provided tax advice. Counsel Matthew R. Silver provided 1940 Act advice. Members of the Davis Polk team are based in the Hong Kong, New York and London offices.

Copy link to share post